SearchDictionaryMobileLogin

Intermediate Uveitis (Chronic Cyclitis)

Subscribe to Selected New Research on Intermediate Uveitis
88  relevant articles (9 outcomes, 8 trials/studies) found for this Disease

Description: Inflammation of the pars plana, ciliary body, and adjacent structures.

Also Known As:
Chronic Cyclitis; Uveitis, Intermediate; Cyclitis, Chronic

Relationship Network

Disease Context: Research Results

-
Eye Diseases: 1244
-
Uveal Diseases: 13
-
Uveitis: 3280
-
Intermediate Uveitis: 88
*
Pars Planitis: 56

Related Diseases

1. Panuveitis
2. Anterior Uveitis
3. Uveitis
4. Sympathetic Ophthalmia (Sympathetic Uveitis)
5. Retinal Vasculitis

Experts

1. Xu, Ge-Zhi: 1 article (01/2008)
2. Shen, Xi: 1 article (01/2008)
3. Gürlü, Vuslat Pelitli: 1 article (02/2007)
4. Kamboj, Bela: 1 article (02/2007)
5. Khemchandani, Mohit: 1 article (02/2007)
6. Esgin, Haluk: 1 article (02/2007)
7. Chawla, Shobhit: 1 article (02/2007)
8. Alimgil, Murat Levent: 1 article (02/2007)
9. Venkatesh, Pradeep: 1 article (01/2007)
10. Vohra, Rajpal: 1 article (01/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Intermediate Uveitis:
1. Triamcinolone Acetonide (Azmacort)FDA LinkGeneric
2. Cyclosporine (Ciclosporin)FDA LinkGeneric
3. Adrenal Cortex Hormones (Corticosteroids)IBA
4. Methotrexate (Mexate)FDA LinkGeneric
5. Retinaldehyde (Retinal)IBA
6. Interleukin-2 (IL2)IBA
03/01/2005 - "RESULTS: Serum concentrations of IL-2 s Ralpha were significantly increased in patients with posterior (p < 0.005) and intermediate uveitis (p < 0.005) as compared to healthy controls"
01/01/1993 - "The serum interleukin-2 receptor levels of patients with ocular Behçet's disease were significantly different from the levels of both the control and the intermediate uveitis groups (P < .001)"
01/01/1993 - "The mean serum interleukin-2 receptor level was 412.6 +/- 94.6 U/ml for the control group, 465.0 +/- 96.6 U/ml for the patients with intermediate uveitis, and 810.9 +/- 369.3 U/ml for those with ocular Behçet's disease"
05/01/2005 - "PURPOSE: To assess the feasibility of a study design that may determine whether subcutaneous administration of the interleukin-2 receptor antibody daclizumab can safely reduce the dependence on standard systemic corticosteroids or other immunosuppressive regimens in patients with sight-threatening, noninfectious intermediate uveitis, posterior uveitis, or panuveitis"
03/01/2004 - "METHODS: Peripheral blood lymphocytes of 18 patients with idiopathic intermediate uveitis and 6 patients with presumed sarcoid intermediate uveitis were evaluated for CD4(+) T cell expression of CD69, CCR4, CCR5, CXCR3 and the intracellular cytokines IFNgamma, TNFalpha, and interleukin (IL)-10 by flow cytometry, and for IL-2, IL-4, IL-5, IL-10, IFNgamma, and TNFalpha production following unstimulated and activated culture using cytokine bead array and compared with healthy control subjects"
Order ALL the reference details at left...
7. Cytostatic AgentsIBA
8. Interleukin-8 (Interleukin 8)IBA
9. Azathioprine (Imuran)FDA LinkGeneric
10. Procarbazine (Matulane)FDA Link

Therapies and Procedures

1. Vitrectomy
2. Phacoemulsification
3. Intraocular Lenses (Intraocular Lens)
4. Intraocular Lens Implantation
5. Corneal Transplantation (Keratoplasty)

Best Treatments:
Research Summary Report
on Intermediate Uveitis
*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 9 Outcomes
  • Top 54 Key Drugs and Biologics
  • Top 13 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>